Vaxart (VXRT) Proxy filing summary

Executive summary

• Strategic actions have been taken to advance the pipeline and drive shareholder value, emphasizing the board's expertise.

• Focus remains on developing oral recombinant vaccines for various indications, leveraging a proprietary pill-based delivery platform.

• Forward-looking statements highlight expectations for clinical trial results, regulatory milestones, and strategic partnerships.

Voting matters and shareholder proposals

• Shareholders are urged to vote the WHITE proxy card for all six board nominees and withhold votes from dissident nominees.

• The board asserts that dissident nominees lack relevant clinical-stage biotech experience and credible value creation ideas.

Board of directors and corporate governance

• The board is promoted as highly qualified and experienced, positioned to guide the company through critical decisions.

• Emphasis is placed on the board's proven execution and leadership during a pivotal period.